Mackenzie Financial’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $152M | Sell |
|
|||||
|
2025
Q1 | $151M | Buy |
|
|||||
|
2024
Q4 | $180M | Buy |
|
|||||
|
2024
Q3 | $191M | Buy |
|
|||||
|
2024
Q2 | $192M | Sell |
|
|||||
|
2024
Q1 | $252M | Buy |
|
|||||
|
2023
Q4 | $217M | Sell |
|
|||||
|
2023
Q3 | $177M | Buy |
|
|||||
|
2023
Q2 | $192M | Buy |
|
|||||
|
2023
Q1 | $175M | Buy |
|
|||||
|
2022
Q4 | $174M | Buy |
|
|||||
|
2022
Q3 | $140M | Sell |
|
|||||
|
2022
Q2 | $211M | Buy |
|
|||||
|
2022
Q1 | $243M | Buy |
|
|||||
|
2021
Q4 | $114M | Sell |
|
|||||
|
2021
Q3 | $127M | Sell |
|
|||||
|
2021
Q2 | $166M | Buy |
|
|||||
|
2021
Q1 | $75.9M | Sell |
|
|||||
|
2020
Q4 | $107M | Buy |
|
|||||
|
2020
Q3 | $83.5M | Buy |
|
|||||
|
2020
Q2 | $63.8M | Buy |
|
|||||
|
2020
Q1 | $33M | Buy |
|
|||||
|
2019
Q4 | $38.9M | Buy |
|
|||||
|
2019
Q3 | $24.5M | Buy |
|
|||||
|
2019
Q2 | $255K | Sell |
|
|||||
|
2019
Q1 | $4.24M | Buy |
|
|||||
|
2018
Q2 | – | Sell |
|
|||||
|
2018
Q1 | $76.8M | Sell |
|
|||||
|
2017
Q4 | $117M | Buy |
|
|||||
|
2017
Q3 | $100M | Buy |
|
|||||
|
2017
Q2 | $51.7M | Buy |
|
|||||
|
2017
Q1 | $41.5M | Hold |
|
|||||
|
2016
Q4 | $35.2M | Buy |
|
|||||
|
2016
Q3 | $3.4M | Buy |
|
|||||
|
2016
Q2 | $2.95M | Buy |
|